224 related articles for article (PubMed ID: 30415086)
1. Natural and modified IL-2 for the treatment of cancer and autoimmune diseases.
Mizui M
Clin Immunol; 2019 Sep; 206():63-70. PubMed ID: 30415086
[TBL] [Abstract][Full Text] [Related]
2. Low-dose IL-2 therapy in autoimmune diseases: An update review.
Zhang R; Zhao Y; Chen X; Zhuang Z; Li X; Shen E
Int Rev Immunol; 2024 May; 43(3):113-137. PubMed ID: 37882232
[TBL] [Abstract][Full Text] [Related]
3. Fine tuning subsets of CD4
Zhao Z; Zhang X; Su L; Xu L; Zheng Y; Sun J
Int Immunopharmacol; 2018 Mar; 56():269-276. PubMed ID: 29414661
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases.
Raeber ME; Sahin D; Karakus U; Boyman O
EBioMedicine; 2023 Apr; 90():104539. PubMed ID: 37004361
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease.
Heiler S; Lötscher J; Kreuzaler M; Rolink J; Rolink A
Front Immunol; 2018; 9():656. PubMed ID: 29670626
[TBL] [Abstract][Full Text] [Related]
6. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
7. New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases.
Xu L; Song X; Su L; Zheng Y; Li R; Sun J
Int Immunopharmacol; 2019 Jul; 72():322-329. PubMed ID: 31005777
[TBL] [Abstract][Full Text] [Related]
8. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases.
Klatzmann D; Abbas AK
Nat Rev Immunol; 2015 May; 15(5):283-94. PubMed ID: 25882245
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.
Rosenzwajg M; Churlaud G; Hartemann A; Klatzmann D
Curr Diab Rep; 2014 Dec; 14(12):553. PubMed ID: 25344788
[TBL] [Abstract][Full Text] [Related]
10. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease.
Boyman O; Surh CD; Sprent J
Expert Opin Biol Ther; 2006 Dec; 6(12):1323-31. PubMed ID: 17223740
[TBL] [Abstract][Full Text] [Related]
11. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
12. New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases.
Jin D; Jiang Y; Chang L; Wei J; Sun J
Int Immunopharmacol; 2022 Sep; 110():108935. PubMed ID: 35732097
[TBL] [Abstract][Full Text] [Related]
13. Restoring regulation - IL-2 therapy in systemic lupus erythematosus.
Humrich JY; Riemekasten G
Expert Rev Clin Immunol; 2016 Nov; 12(11):1153-1160. PubMed ID: 27283871
[TBL] [Abstract][Full Text] [Related]
14. Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity.
Zhou P
Cytokine Growth Factor Rev; 2022 Oct; 67():80-88. PubMed ID: 35803833
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of interleukin-2 in autoimmune diseases.
Yuan Y; Kolios AGA; Liu Y; Zhang B; Li H; Tsokos GC; Zhang X
Trends Mol Med; 2022 Jul; 28(7):596-612. PubMed ID: 35624009
[TBL] [Abstract][Full Text] [Related]
16. Manipulating IL-2 and IL-2R in autoimmune diseases and transplantation.
Zhang M; Tang Q
Immunotherapy; 2015; 7(12):1231-4. PubMed ID: 26601714
[No Abstract] [Full Text] [Related]
17. Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.
Ballesteros-Tato A
Immunotherapy; 2014; 6(11):1207-20. PubMed ID: 25496335
[TBL] [Abstract][Full Text] [Related]
18. A single-agent fusion of human IL-2 and anti-IL-2 antibody that selectively expands regulatory T cells.
Lin Y; Wang X; Qin Y; Wang C; Zhou T; Zhang L; Su L; Ren W; Liao C
Commun Biol; 2024 Mar; 7(1):299. PubMed ID: 38461332
[TBL] [Abstract][Full Text] [Related]
19. Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101.
Sredni B; Tichler T; Shani A; Catane R; Kaufman B; Strassmann G; Albeck M; Kalechman Y
J Natl Cancer Inst; 1996 Sep; 88(18):1276-84. PubMed ID: 8797767
[TBL] [Abstract][Full Text] [Related]
20. Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases.
Tomasovic LM; Liu K; VanDyke D; Fabilane CS; Spangler JB
BioDrugs; 2024 Mar; 38(2):227-248. PubMed ID: 37999893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
